Skip to content

Impact of Thermocoagulation During Invasive EEG Monitoring in Children With Focal Drug-resistant Epilepsies

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02886650
Acronym
COAG
Enrollment
100
Registered
2016-09-01
Start date
2015-12-01
Completion date
2024-05-28
Last updated
2026-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Keywords

Paediatrics, epilepsy surgery, genetic mutation, focal seizures

Brief summary

When focal epilepsies become drug-resistant, it could be eligible for cortical surgical resection. Therefore, an invasive EEG monitoring with depth electrodes is often needed during presurgical evaluation. Some of these children can have access to thermocoagulation inside the ictal onset zone, at the end of the monitoring and before to remove the electrodes. These thermocoagulations can disorganize the epileptogenic network thanks to millimetric cortical lesions around the electrodes. The aim is to stop or at least, to reduce the seizure frequency for few weeks or months. This could be a benefit for the child, and also a confirmation of the ictal onset zone and guide the surgeon. This technique is currently used in adult population for years, but remains very rare in children.

Interventions

Thermocoagulation During pre-surgical Invasive EEG Monitoring

Sponsors

Fondation Ophtalmologique Adolphe de Rothschild
Lead SponsorNETWORK

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Months to 17 Years
Healthy volunteers
No

Inclusion criteria

* age 18 month to 17 years old * focal drug-resistant epilepsy * small size lesion (1 or 2 gyri) or cryptogenic epilepsy * indication for EEG monitoring with depth electrodes during presurgical evaluation

Exclusion criteria

* formal contraindication to surgery or anaesthesia * functional area or potentially large epileptic area * refusal to participate in the study * no health insurance coverage

Design outcomes

Primary

MeasureTime frame
Number of children with a decrease of at least 50% of the seizure frequencyone month after surgery

Countries

France

Contacts

PRINCIPAL_INVESTIGATORMathilde CHIPAUX, MD

Fondation OPH A de Rothschild

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 16, 2026